State of Wisconsin Investment Board reduced its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 14.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,112 shares of the biopharmaceutical company’s stock after selling 3,140 shares during the quarter. State of Wisconsin Investment Board’s holdings in ACADIA Pharmaceuticals were worth $533,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. First Trust Advisors LP raised its holdings in ACADIA Pharmaceuticals by 60.8% during the 2nd quarter. First Trust Advisors LP now owns 1,402,029 shares of the biopharmaceutical company’s stock worth $39,103,000 after purchasing an additional 530,103 shares during the last quarter. National Planning Corp raised its holdings in ACADIA Pharmaceuticals by 7.8% during the 2nd quarter. National Planning Corp now owns 34,680 shares of the biopharmaceutical company’s stock worth $987,000 after purchasing an additional 2,500 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in ACADIA Pharmaceuticals by 6.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 389,127 shares of the biopharmaceutical company’s stock worth $10,853,000 after purchasing an additional 24,165 shares during the last quarter. Pictet Asset Management Ltd. raised its holdings in ACADIA Pharmaceuticals by 20.6% during the 2nd quarter. Pictet Asset Management Ltd. now owns 945,838 shares of the biopharmaceutical company’s stock worth $24,318,000 after purchasing an additional 161,600 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC raised its holdings in ACADIA Pharmaceuticals by 25.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 11,189 shares of the biopharmaceutical company’s stock worth $312,000 after purchasing an additional 2,243 shares during the last quarter. 97.11% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/13/state-of-wisconsin-investment-board-sells-3140-shares-of-acadia-pharmaceuticals-inc-acad.html.

Shares of ACADIA Pharmaceuticals Inc. (ACAD) opened at 37.17 on Wednesday. ACADIA Pharmaceuticals Inc. has a 52 week low of $20.68 and a 52 week high of $40.83. The company’s market capitalization is $4.55 billion. The stock has a 50 day moving average price of $32.16 and a 200-day moving average price of $31.55.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The company had revenue of $30.50 million during the quarter, compared to the consensus estimate of $20.02 million. During the same period last year, the company earned ($0.63) earnings per share. The firm’s revenue was up 30400.0% compared to the same quarter last year. Equities research analysts expect that ACADIA Pharmaceuticals Inc. will post ($2.55) EPS for the current year.

In other news, EVP Glenn Baity sold 38,097 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $30.00, for a total transaction of $1,142,910.00. Following the completion of the transaction, the executive vice president now directly owns 109,253 shares in the company, valued at $3,277,590. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 80,829 shares of company stock valued at $2,623,850 over the last 90 days. 22.25% of the stock is owned by corporate insiders.

ACAD has been the subject of several recent research reports. BidaskClub raised ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 21st. Zacks Investment Research raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a report on Tuesday, July 11th. Rodman & Renshaw reissued a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, May 22nd. ValuEngine raised ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Piper Jaffray Companies set a $54.00 price objective on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $43.23.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Stock Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.